Trial Profile
Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2013
Price :
$35
*
At a glance
- Drugs PUR 003 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- 21 May 2012 Results were presented at the International Conference of the American Thoracic Society (ATS) in May 2012.
- 21 Nov 2011 Actual end date changed from May 2011 to Oct 2011 as reported by ClinicalTrials.gov.
- 28 Mar 2011 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.